Henan Cancer Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1977-01-01
- Employees
- -
- Market Cap
- -
Evaluation of Neoadjuvant Therapy Efficacy and Postoperative Pathological Indicators in Esophageal Cancer Using CT and Multimodal MRI
Not yet recruiting
- Conditions
- Esophageal CancerNeoadjuvant Therapy
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT06833775
SHR-A2102 Combined with Adebrelimab As Neoadjuvant Therapy for Early Triple-Negative Breast Cancer
Phase 2
Not yet recruiting
- Conditions
- TNBC - Triple-Negative Breast Cancer
- Interventions
- Drug: SHR-A2102 ; Adebrelimab injection
- First Posted Date
- 2025-02-11
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT06819319
Nab-P+Cb+PD1 Inhibitors Combined/not Combined with Bevacizumab As Neoadjuvant Therapy for Early TNBC
Phase 2
Recruiting
- Conditions
- Triple-negative Breast Cancer
- Interventions
- Drug: 6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1)Drug: 6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1)Drug: 6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 ( d 1)+5*Bevacizumab ( d 1)Drug: 6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 ( d 1)+5*Bevacizumab ( d 1)
- First Posted Date
- 2025-02-10
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 64
- Registration Number
- NCT06817525
- Locations
- 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China
Mechanistic Study on the Diagnosis of Esophageal Cancer Lymph Node Metastasis Using Spectral CT, Multimodal MRI, FAPI PET-CT, Pathology, and AI Evaluation System
Not yet recruiting
- Conditions
- Esophageal Cancer
- First Posted Date
- 2025-02-10
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT06818214
Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia
Phase 2
Not yet recruiting
- Conditions
- SCLC, Extensive Stage
- Interventions
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT06793228
- Locations
- 🇨🇳
The First Affiliated Hospital of Henan University of Science and Technolog, Luoyang, Henan, China
🇨🇳Xinxiang Central Hospital, Xinxiang, Henan, China
🇨🇳Henan cancer hospital,, Zhengzhou, Henan, China
Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 55
- Registration Number
- NCT06786208
- Locations
- 🇨🇳
Qiming Wang, Zhengzhou, Henan, China
NabPE with or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 709
- Registration Number
- NCT06781281
- Locations
- 🇨🇳
Henan cancer hospital, Zhengzhou, China
A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG
Phase 2
Recruiting
- Conditions
- Gastric/Gastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2025-01-14
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 69
- Registration Number
- NCT06774222
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, China
Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma
Phase 2
Recruiting
- Conditions
- Unresectable Biliary Tract Carcinoma
- Interventions
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 63
- Registration Number
- NCT06749730
- Locations
- 🇨🇳
HeNan, Zhengzhou, China
Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study
Phase 2
Not yet recruiting
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Drug: hepatic arterial infusion of recombinant human type 5 adenovirus
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 11
- Registration Number
- NCT06685354
- Locations
- 🇨🇳
The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
© Copyright 2025. All Rights Reserved by MedPath